Advertisement

The Type and the Position of HNF1A Mutation Modulate Age at Diagnosis of Diabetes in Patients with Maturity-Onset Diabetes of the Young (MODY)-3

  1. Christine Bellanné-Chantelot1,
  2. Claire Carette2,
  3. Jean-Pierre Riveline3,
  4. René Valéro4,
  5. Jean-François Gautier5,
  6. Etienne Larger69,
  7. Yves Reznik7,
  8. Pierre-Henri Ducluzeau8,
  9. Agnès Sola9,
  10. Agnès Hartemann-Heurtier10,
  11. Pierre Lecomte11,
  12. Lucy Chaillous12,
  13. Marie Laloi-Michelin13,
  14. Jean-Marie Wilhem14,
  15. Pierre Cuny15,
  16. Françoise Duron16,
  17. Bruno Guerci17,
  18. Nathalie Jeandidier18,
  19. Helen Mosnier-Pudar19,
  20. Michel Assayag20,
  21. Danièle Dubois-Laforgue2,
  22. Gilberto Velho21 and
  23. José Timsit2
  1. 1Department of Genetics, AP-HP Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie-Paris6, Paris, France
  2. 2Department of Immunology and Diabetology, AP-HP Hôpital Cochin, Université René Descartes- Paris5, and Inserm, Research Unit 561, Paris, France
  3. 3Department of Endocrinology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
  4. 4Department of Nutrition-Metabolic Diseases-Endocrinology, AP-HM CHU de la Timone, Marseille, France
  5. 5Department of Endocrinology, AP-HP Hôpital Saint-Louis, Université Denis Diderot-Paris7, Paris, France
  6. 6Department of Diabetology, AP-HP Hôpital Bichat, Paris, France
  7. 7Department of Endocrinology, CHU Caen, Caen, France
  8. 8Department of Endocrinology, CHU Angers, Angers, France
  9. 9Department of Diabetology, AP-HP Hôpital Hôtel Dieu, Paris, France
  10. 10Department of Diabetology, AP-HP Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie-Paris6, Paris, France
  11. 11Department of Endocrinology, CHU Bretonneau, Tours, France
  12. 12Department of Endocrinology, CHU Nantes, Nantes, France
  13. 13Department of Internal Medicine, AP-HP Hôpital Lariboisière, Paris, France
  14. 14Department of Internal Medicine, Centre Hospitalier Saint-Morand, Altkirch, France
  15. 15Department of Diabetology, Hôpital Beauregard, Thionville, France
  16. 16Department of Endocrinology, AP-HP Hôpital Saint-Antoine, Paris, France
  17. 17Department of Diabetology, CHU Nancy, Nancy, France
  18. 18Department of Diabetology, CHU Strasbourg, Strasbourg, France
  19. 19Department of Endocrinology, AP-HP Hôpital Cochin, Université Paris 5, Paris, France
  20. 20Department of Internal Medicine, Centre Hospitalier Compiègne, Compiègne, France
  21. 21Inserm, Research Unit 695, Paris, France
  1. Address correspondence and reprint requests to Christine Bellanné-Chantelot, Département de Génétique, Groupe Hospitalier Pitié-Salpétrière, Bât 6 rue Lapeyronie, 47/83 Boulevard de l’Hôpital, 75651 Paris Cedex 13, France. E-mail: christine.bellanne-chantelot{at}psl.aphp.fr

Abstract

OBJECTIVE—The clinical expression of maturity-onset diabetes of the young (MODY)-3 is highly variable. This may be due to environmental and/or genetic factors, including molecular characteristics of the hepatocyte nuclear factor 1-α (HNF1A) gene mutation.

RESEARCH DESIGN AND METHODS—We analyzed the mutations identified in 356 unrelated MODY3 patients, including 118 novel mutations, and searched for correlations between the genotype and age at diagnosis of diabetes.

RESULTS—Missense mutations prevailed in the dimerization and DNA-binding domains (74%), while truncating mutations were predominant in the transactivation domain (62%). The majority (83%) of the mutations were located in exons 1- 6, thus affecting the three HNF1A isoforms. Age at diagnosis of diabetes was lower in patients with truncating mutations than in those with missense mutations (18 vs. 22 years, P = 0.005). Missense mutations affecting the dimerization/DNA-binding domains were associated with a lower age at diagnosis than those affecting the transactivation domain (20 vs. 30 years, P = 10−4). Patients with missense mutations affecting the three isoforms were younger at diagnosis than those with missense mutations involving one or two isoforms (P = 0.03).

CONCLUSIONS—These data show that part of the variability of the clinical expression in MODY3 patients may be explained by the type and the location of HNF1A mutations. These findings should be considered in studies for the search of additional modifier genetic factors.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 14 November 2007. DOI: 10.2337/db07-0859.

  • Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0859.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted November 7, 2007.
    • Received June 26, 2007.
| Table of Contents
Advertisement